Lacrimal gland pleomorphic adenoma: a review of 52 cases, 15-year experience

Proptosis Revealing a Rare Lacrimal Gland Tumor: A Case of Chondroid Syringoma in a 35-year-old Patient

“… 1 , 5 , 9 LGCS develops mainly in the orbital lobe of the gland, and patients present with progressive painless proptosis with sometimes axial deviation. 5 , 9 , 11 - 13 These symptoms have typically long duration, beyond 10 months. 5 , 9 The present case had these classic clinical features with long duration of about 2 years.…”

“… 5 , 9 , 11 - 13 These symptoms have typically long duration, beyond 10 months. 5 , 9 The present case had these classic clinical features with long duration of about 2 years. The painless symptoms obviously explain why patients seek clinical attention belatedly.…”

“…9,10 The tumor is usually found in adult-patients with a mean age around 38 to 47 years, and there is no gender or side predilection. 1,5,9 LGCS develops mainly in the orbital lobe of the gland, and patients present with progressive painless proptosis with sometimes axial deviation. 5,9,[11][12][13] These symptoms have typically long duration, beyond 10 months.…”

“… 2 - 4 Pleomorphic adenoma is the main epithelial tumor of the lacrimal gland. 3 - 5 Pleomorphic adenoma is a well known benign tumor commonly found in salivary glands, however it can be found elsewhere with different names: mixed benign tumor or chondroid syringoma especially in sweat glands. 6 - 8 Lacrimal gland chondroid syringoma (LGCS) is a very rare tumor with some characteristic clinico-radiological features that could be used for appropriate patient’s management as this neoplasm has potential for recurrence and malignant transformation.…”

Cross-Sectional Imaging In Ocular And Orbital Lesions A Review

“…Bone erosion, nodularity or infiltrative borders should raise suspicion for malignancy. 27 Treatment consists of en-bloc removal of the tumor without biopsy, with excellent prognosis. Incomplete excision or rupture of the tumor may lead to recurrence or malignant transformation to pleomorphic adenocarcinoma.…”